LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Tarsus Pharmaceuticals today and set a price target of $85.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD’s rating is based on the impressive financial performance and growth potential of Tarsus Pharmaceuticals. The company reported a significant increase in Xdemvy sales, surpassing previous guidance with $102.7 million in net sales for the quarter. This growth is supported by broad payer coverage, a large and expanding prescriber base, and effective direct-to-consumer campaigns. These factors contribute to a positive outlook for continued momentum in sales.
Cory Jubinville, PhD also highlights the improvement in gross-to-net discounts and the company’s strong cash position, which further bolster confidence in Tarsus Pharmaceuticals’ financial health. The company’s strategic initiatives, such as expanding its prescriber base and increasing retreatment rates, are expected to drive future growth. With these factors in mind, the Buy rating reflects the potential for sustained performance and value creation for investors.
According to TipRanks, Jubinville, PhD is a 3-star analyst with an average return of 1.8% and a 41.49% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Mereo Biopharma Group Plc, and Rocket Pharmaceuticals.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $72.00 price target.